User login
AGA Giving Day: Our fight to eradicate disparities in digestive diseases
On Dec. 3, AGA brought together the GI community in an effort to fund health disparity research with the goal of improving care for the patients who rely on us.
The patients we serve face racial health disparities daily. It’s our responsibility to take action. With money raised through this campaign, the AGA Research Foundation will fund research projects that help understand health disparities and create strategies for overcoming them.
AGA Giving Day was the opportunity to do something about this important societal issue as it directly relates to our field. We all have a role to play in creating a just world free of health disparities in digestive diseases and free of inequities in access and effective health care delivery.
The AGA Research Foundation’s AGA Giving Day effort will help support state-of-the-art research that aligns with the realities of the current multicultural patient population and disease states to achieve health equity for all.
Learn more at gastro.org/agagivingday.
On Dec. 3, AGA brought together the GI community in an effort to fund health disparity research with the goal of improving care for the patients who rely on us.
The patients we serve face racial health disparities daily. It’s our responsibility to take action. With money raised through this campaign, the AGA Research Foundation will fund research projects that help understand health disparities and create strategies for overcoming them.
AGA Giving Day was the opportunity to do something about this important societal issue as it directly relates to our field. We all have a role to play in creating a just world free of health disparities in digestive diseases and free of inequities in access and effective health care delivery.
The AGA Research Foundation’s AGA Giving Day effort will help support state-of-the-art research that aligns with the realities of the current multicultural patient population and disease states to achieve health equity for all.
Learn more at gastro.org/agagivingday.
On Dec. 3, AGA brought together the GI community in an effort to fund health disparity research with the goal of improving care for the patients who rely on us.
The patients we serve face racial health disparities daily. It’s our responsibility to take action. With money raised through this campaign, the AGA Research Foundation will fund research projects that help understand health disparities and create strategies for overcoming them.
AGA Giving Day was the opportunity to do something about this important societal issue as it directly relates to our field. We all have a role to play in creating a just world free of health disparities in digestive diseases and free of inequities in access and effective health care delivery.
The AGA Research Foundation’s AGA Giving Day effort will help support state-of-the-art research that aligns with the realities of the current multicultural patient population and disease states to achieve health equity for all.
Learn more at gastro.org/agagivingday.
Top AGA Community patient cases
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Practice update: Small intestinal bacteria overgrowth (SIBO) (https://community.gastro.org/posts/22838)
Case: Polypectomy with low neutrophils (https://community.gastro.org/posts/22844)
Case: Esophagus adenocarcinoma after sleeve gastrectomy (https://community.gastro.org/posts/22868)
Case: Restarting infliximab after shingles – when is it safe? (https://community.gastro.org/posts/22890)
Case: Flatulence in Colorado (https://community.gastro.org/posts/22901)
Case: Serrated epithelial change (SEC) in IBD (https://community.gastro.org/posts/22948)
Case: Multiloculated pancreatic cyst (https://community.gastro.org/posts/22935)
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Practice update: Small intestinal bacteria overgrowth (SIBO) (https://community.gastro.org/posts/22838)
Case: Polypectomy with low neutrophils (https://community.gastro.org/posts/22844)
Case: Esophagus adenocarcinoma after sleeve gastrectomy (https://community.gastro.org/posts/22868)
Case: Restarting infliximab after shingles – when is it safe? (https://community.gastro.org/posts/22890)
Case: Flatulence in Colorado (https://community.gastro.org/posts/22901)
Case: Serrated epithelial change (SEC) in IBD (https://community.gastro.org/posts/22948)
Case: Multiloculated pancreatic cyst (https://community.gastro.org/posts/22935)
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Practice update: Small intestinal bacteria overgrowth (SIBO) (https://community.gastro.org/posts/22838)
Case: Polypectomy with low neutrophils (https://community.gastro.org/posts/22844)
Case: Esophagus adenocarcinoma after sleeve gastrectomy (https://community.gastro.org/posts/22868)
Case: Restarting infliximab after shingles – when is it safe? (https://community.gastro.org/posts/22890)
Case: Flatulence in Colorado (https://community.gastro.org/posts/22901)
Case: Serrated epithelial change (SEC) in IBD (https://community.gastro.org/posts/22948)
Case: Multiloculated pancreatic cyst (https://community.gastro.org/posts/22935)
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
CGH releases its first GI cancer-themed issue
Articles include guidance on cancer progression in Barrett’s esophagus patients, CRC surveillance, and HCC incidence and risk.
Clinical Gastroenterology and Hepatology (CGH) is proud to release its first themed issue on GI cancers. This “issue within an issue” includes a collection of articles, selected by editor-in-chief Dr. Fasiha Kanwal, that will provide you with practical research to help guide cancer prevention, surveillance and treatment decisions for your patients.
View the themed issue on CGH’s website. and access other curated collections on cghjournal.org.
How can we combat health disparities in GI?
Hear from Craig Munroe, MD, on why we all need to donate to AGA Giving Day, now through Dec. 3, in order to fund GI health disparities research.
“Health disparities exist and negatively impact patients every day across our country. Working to solve these inequities for the good of our patients and workforce is fundamental to our calling as physicians,” says Craig A. Munroe, MD, associate chief for clinical innovation, University of California, San Francisco, AGA Diversity Committee member, AGA Equity Project advisory board member. “Although we have made tremendous strides over the decades, there is still much more that needs to be done. Disparate systems of care and legacies of inequality continue to cause great harm.”
That is why AGA is bringing together the GI community to fund health disparity research with the goal of improving care for all patients. With contributions raised through AGA Giving Day campaign, the AGA Research Foundation will fund research projects that help us understand health disparities and create strategies for overcoming them.
“I’m donating to AGA Giving Day because I believe the work being done will have an immediate positive impact, and will continue to benefit future generations of patients, physicians, scientists, health providers, and trainees.”
Please join Dr. Munroe and your AGA colleagues in making a tax-deductible donation to the AGA Research Foundation to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases. www.Gastro.org/GivingDay
Articles include guidance on cancer progression in Barrett’s esophagus patients, CRC surveillance, and HCC incidence and risk.
Clinical Gastroenterology and Hepatology (CGH) is proud to release its first themed issue on GI cancers. This “issue within an issue” includes a collection of articles, selected by editor-in-chief Dr. Fasiha Kanwal, that will provide you with practical research to help guide cancer prevention, surveillance and treatment decisions for your patients.
View the themed issue on CGH’s website. and access other curated collections on cghjournal.org.
How can we combat health disparities in GI?
Hear from Craig Munroe, MD, on why we all need to donate to AGA Giving Day, now through Dec. 3, in order to fund GI health disparities research.
“Health disparities exist and negatively impact patients every day across our country. Working to solve these inequities for the good of our patients and workforce is fundamental to our calling as physicians,” says Craig A. Munroe, MD, associate chief for clinical innovation, University of California, San Francisco, AGA Diversity Committee member, AGA Equity Project advisory board member. “Although we have made tremendous strides over the decades, there is still much more that needs to be done. Disparate systems of care and legacies of inequality continue to cause great harm.”
That is why AGA is bringing together the GI community to fund health disparity research with the goal of improving care for all patients. With contributions raised through AGA Giving Day campaign, the AGA Research Foundation will fund research projects that help us understand health disparities and create strategies for overcoming them.
“I’m donating to AGA Giving Day because I believe the work being done will have an immediate positive impact, and will continue to benefit future generations of patients, physicians, scientists, health providers, and trainees.”
Please join Dr. Munroe and your AGA colleagues in making a tax-deductible donation to the AGA Research Foundation to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases. www.Gastro.org/GivingDay
Articles include guidance on cancer progression in Barrett’s esophagus patients, CRC surveillance, and HCC incidence and risk.
Clinical Gastroenterology and Hepatology (CGH) is proud to release its first themed issue on GI cancers. This “issue within an issue” includes a collection of articles, selected by editor-in-chief Dr. Fasiha Kanwal, that will provide you with practical research to help guide cancer prevention, surveillance and treatment decisions for your patients.
View the themed issue on CGH’s website. and access other curated collections on cghjournal.org.
How can we combat health disparities in GI?
Hear from Craig Munroe, MD, on why we all need to donate to AGA Giving Day, now through Dec. 3, in order to fund GI health disparities research.
“Health disparities exist and negatively impact patients every day across our country. Working to solve these inequities for the good of our patients and workforce is fundamental to our calling as physicians,” says Craig A. Munroe, MD, associate chief for clinical innovation, University of California, San Francisco, AGA Diversity Committee member, AGA Equity Project advisory board member. “Although we have made tremendous strides over the decades, there is still much more that needs to be done. Disparate systems of care and legacies of inequality continue to cause great harm.”
That is why AGA is bringing together the GI community to fund health disparity research with the goal of improving care for all patients. With contributions raised through AGA Giving Day campaign, the AGA Research Foundation will fund research projects that help us understand health disparities and create strategies for overcoming them.
“I’m donating to AGA Giving Day because I believe the work being done will have an immediate positive impact, and will continue to benefit future generations of patients, physicians, scientists, health providers, and trainees.”
Please join Dr. Munroe and your AGA colleagues in making a tax-deductible donation to the AGA Research Foundation to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases. www.Gastro.org/GivingDay
Congrats to these five AGA members
We’re proud to share the news of two AGA members elected to the prestigious National Academy of Medicine and three honored with the 2020 Sherman Prize.
Congratulations to AGA members Judy H. Cho, MD, and B. Mark Evers, MD, who were recently elected to the National Academy of Medicine.
Judy H. Cho, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, New York, for “establishing that uncommon, loss-of-function variants in the microbial-sensing domain of NOD2 confer risk for Crohn’s disease, and identifying a loss-of-function allele in the IL-23 receptor that protects against Crohn’s disease and ulcerative colitis, leading to new, approved therapies.”
B. Mark Evers, MD, physician in chief of oncology service at University of Kentucky Healthcare, for “his expertise on intestinal hormones and hormonal arcades in oncogenesis. His seminal insights defined the role of gut hormones on normal physiology and metabolism, pioneering innovative understanding of neuroendocrine cell biology and the role of neurohormonal pathways in the development and progression of neuroendocrine tumors.”
Being selected to the Academy is one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
In addition, the 2020 Sherman Prize was awarded to the following three AGA members:
David Rubin, MD, AGAF, chief, section of gastroenterology, hepatology and nutrition at University of Chicago Medicine, for his “renown in the IBD community as a brilliant clinician, creative researcher, tireless advocate, and trailblazing educator.”
Gary Wu, MD, professor of medicine at University of Pennsylvania, Perelman School of Medicine, for “pioneering the study of the gut microbiome in IBD, publishing seminal research on the relationship between diet and the microbiome — enabling multiple areas of research into dietary interventions for IBD.“
Jessica Allegretti, MD, MPH, director of clinical trials at Brigham and Women’s Hospital, as a “highly regarded expert in the field of fecal microbiota transplantation (FMT) and microbiome therapeutics, establishing the therapy as an effective treatment in IBD patients with recurrent C. difficile.”
Presented by the Bruce and Cynthia Sherman Charitable Foundation, the Sherman Prize is awarded to experts in the field of Crohn’s disease and ulcerative colitis who have exhibited their commitment to advancing inflammatory bowel disease care and have dedicated their careers to overcome these diseases.
We’re proud to share the news of two AGA members elected to the prestigious National Academy of Medicine and three honored with the 2020 Sherman Prize.
Congratulations to AGA members Judy H. Cho, MD, and B. Mark Evers, MD, who were recently elected to the National Academy of Medicine.
Judy H. Cho, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, New York, for “establishing that uncommon, loss-of-function variants in the microbial-sensing domain of NOD2 confer risk for Crohn’s disease, and identifying a loss-of-function allele in the IL-23 receptor that protects against Crohn’s disease and ulcerative colitis, leading to new, approved therapies.”
B. Mark Evers, MD, physician in chief of oncology service at University of Kentucky Healthcare, for “his expertise on intestinal hormones and hormonal arcades in oncogenesis. His seminal insights defined the role of gut hormones on normal physiology and metabolism, pioneering innovative understanding of neuroendocrine cell biology and the role of neurohormonal pathways in the development and progression of neuroendocrine tumors.”
Being selected to the Academy is one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
In addition, the 2020 Sherman Prize was awarded to the following three AGA members:
David Rubin, MD, AGAF, chief, section of gastroenterology, hepatology and nutrition at University of Chicago Medicine, for his “renown in the IBD community as a brilliant clinician, creative researcher, tireless advocate, and trailblazing educator.”
Gary Wu, MD, professor of medicine at University of Pennsylvania, Perelman School of Medicine, for “pioneering the study of the gut microbiome in IBD, publishing seminal research on the relationship between diet and the microbiome — enabling multiple areas of research into dietary interventions for IBD.“
Jessica Allegretti, MD, MPH, director of clinical trials at Brigham and Women’s Hospital, as a “highly regarded expert in the field of fecal microbiota transplantation (FMT) and microbiome therapeutics, establishing the therapy as an effective treatment in IBD patients with recurrent C. difficile.”
Presented by the Bruce and Cynthia Sherman Charitable Foundation, the Sherman Prize is awarded to experts in the field of Crohn’s disease and ulcerative colitis who have exhibited their commitment to advancing inflammatory bowel disease care and have dedicated their careers to overcome these diseases.
We’re proud to share the news of two AGA members elected to the prestigious National Academy of Medicine and three honored with the 2020 Sherman Prize.
Congratulations to AGA members Judy H. Cho, MD, and B. Mark Evers, MD, who were recently elected to the National Academy of Medicine.
Judy H. Cho, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, New York, for “establishing that uncommon, loss-of-function variants in the microbial-sensing domain of NOD2 confer risk for Crohn’s disease, and identifying a loss-of-function allele in the IL-23 receptor that protects against Crohn’s disease and ulcerative colitis, leading to new, approved therapies.”
B. Mark Evers, MD, physician in chief of oncology service at University of Kentucky Healthcare, for “his expertise on intestinal hormones and hormonal arcades in oncogenesis. His seminal insights defined the role of gut hormones on normal physiology and metabolism, pioneering innovative understanding of neuroendocrine cell biology and the role of neurohormonal pathways in the development and progression of neuroendocrine tumors.”
Being selected to the Academy is one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
In addition, the 2020 Sherman Prize was awarded to the following three AGA members:
David Rubin, MD, AGAF, chief, section of gastroenterology, hepatology and nutrition at University of Chicago Medicine, for his “renown in the IBD community as a brilliant clinician, creative researcher, tireless advocate, and trailblazing educator.”
Gary Wu, MD, professor of medicine at University of Pennsylvania, Perelman School of Medicine, for “pioneering the study of the gut microbiome in IBD, publishing seminal research on the relationship between diet and the microbiome — enabling multiple areas of research into dietary interventions for IBD.“
Jessica Allegretti, MD, MPH, director of clinical trials at Brigham and Women’s Hospital, as a “highly regarded expert in the field of fecal microbiota transplantation (FMT) and microbiome therapeutics, establishing the therapy as an effective treatment in IBD patients with recurrent C. difficile.”
Presented by the Bruce and Cynthia Sherman Charitable Foundation, the Sherman Prize is awarded to experts in the field of Crohn’s disease and ulcerative colitis who have exhibited their commitment to advancing inflammatory bowel disease care and have dedicated their careers to overcome these diseases.
Experts release new management strategies for malignant colorectal polyps
Early identification and removal of cancerous colorectal polyps is critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force (U.S. MSTF) on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for features associated with cancer, discuss how these factors guide management and outline when to advise surgery after malignant polyp removal.
Key recommendations from the U.S. Multisociety Task Force on Colorectal Cancer, which is comprised of leading experts representing AGA, ACG and ASGE, include:
1. Management of malignant polyps must begin with a thorough and knowledgeable endoscopic assessment designed to identify features of deep submucosal invasion.
2. In nonpedunculated lesions with features of deep submucosal invasion, endoscopic biopsy and tattooing should be followed by surgical resection.
3. Nonpedunculated lesions with high risk of superficial submucosal invasion should be considered for en bloc resection and proper specimen handling.
4. When pathology reports cancer in a lesion that was completely resected endoscopically, the decision to recommend surgery is based on polyp shape, whether there was en bloc resection and adequate histologic assessment, the presence or absence of unfavorable histologic features, the patient’s risk for surgical mortality and morbidity, and patient preferences.
For more information, review the full publication: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. The U.S. MSTF recommendations are published jointly in Gastroenterology, The American Journal of Gastroenterology, and Gastrointestinal Endoscopy.
Early identification and removal of cancerous colorectal polyps is critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force (U.S. MSTF) on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for features associated with cancer, discuss how these factors guide management and outline when to advise surgery after malignant polyp removal.
Key recommendations from the U.S. Multisociety Task Force on Colorectal Cancer, which is comprised of leading experts representing AGA, ACG and ASGE, include:
1. Management of malignant polyps must begin with a thorough and knowledgeable endoscopic assessment designed to identify features of deep submucosal invasion.
2. In nonpedunculated lesions with features of deep submucosal invasion, endoscopic biopsy and tattooing should be followed by surgical resection.
3. Nonpedunculated lesions with high risk of superficial submucosal invasion should be considered for en bloc resection and proper specimen handling.
4. When pathology reports cancer in a lesion that was completely resected endoscopically, the decision to recommend surgery is based on polyp shape, whether there was en bloc resection and adequate histologic assessment, the presence or absence of unfavorable histologic features, the patient’s risk for surgical mortality and morbidity, and patient preferences.
For more information, review the full publication: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. The U.S. MSTF recommendations are published jointly in Gastroenterology, The American Journal of Gastroenterology, and Gastrointestinal Endoscopy.
Early identification and removal of cancerous colorectal polyps is critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force (U.S. MSTF) on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for features associated with cancer, discuss how these factors guide management and outline when to advise surgery after malignant polyp removal.
Key recommendations from the U.S. Multisociety Task Force on Colorectal Cancer, which is comprised of leading experts representing AGA, ACG and ASGE, include:
1. Management of malignant polyps must begin with a thorough and knowledgeable endoscopic assessment designed to identify features of deep submucosal invasion.
2. In nonpedunculated lesions with features of deep submucosal invasion, endoscopic biopsy and tattooing should be followed by surgical resection.
3. Nonpedunculated lesions with high risk of superficial submucosal invasion should be considered for en bloc resection and proper specimen handling.
4. When pathology reports cancer in a lesion that was completely resected endoscopically, the decision to recommend surgery is based on polyp shape, whether there was en bloc resection and adequate histologic assessment, the presence or absence of unfavorable histologic features, the patient’s risk for surgical mortality and morbidity, and patient preferences.
For more information, review the full publication: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. The U.S. MSTF recommendations are published jointly in Gastroenterology, The American Journal of Gastroenterology, and Gastrointestinal Endoscopy.
Be among the first to commit to AGA Giving Day
Our patients face racial health disparities daily, leading to inequalities in care and poorer health outcomes.
At this important moment in history, the AGA Research Foundation is uniquely qualified to push forward innovative research in health disparities in gastroenterology. With donations from AGA members to our new initiative called AGA Giving Day, we can provide researchers with a secure source of funding that helps understand the causes of known health disparities, understand why the disparity exists, and develop interventions to reduce and eliminate health disparities.
The AGA Research Foundation invites you to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases.
Learn more at gastro.org/agagivingday.
ginews@gastro.org
Our patients face racial health disparities daily, leading to inequalities in care and poorer health outcomes.
At this important moment in history, the AGA Research Foundation is uniquely qualified to push forward innovative research in health disparities in gastroenterology. With donations from AGA members to our new initiative called AGA Giving Day, we can provide researchers with a secure source of funding that helps understand the causes of known health disparities, understand why the disparity exists, and develop interventions to reduce and eliminate health disparities.
The AGA Research Foundation invites you to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases.
Learn more at gastro.org/agagivingday.
ginews@gastro.org
Our patients face racial health disparities daily, leading to inequalities in care and poorer health outcomes.
At this important moment in history, the AGA Research Foundation is uniquely qualified to push forward innovative research in health disparities in gastroenterology. With donations from AGA members to our new initiative called AGA Giving Day, we can provide researchers with a secure source of funding that helps understand the causes of known health disparities, understand why the disparity exists, and develop interventions to reduce and eliminate health disparities.
The AGA Research Foundation invites you to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases.
Learn more at gastro.org/agagivingday.
ginews@gastro.org
AGA releases largest real-world report on safety and effectiveness of fecal microbiota transplantation
Ninety percent of patients tracked in the AGA FMT National Registry were cured of Clostridioides difficile infection with few serious side effects.
AGA has released the first results from the NIH-funded AGA Fecal Microbiota Transplantation (FMT) National Registry, the largest real-world study on the safety and effectiveness of FMT. Few serious side effects were reported.
“While the value of fecal microbiota transplantation for treating recurrent C. difficile infection is clear from research studies, the potential long-term consequences of altering a patient’s gut microbiota are not fully known,” says Colleen R. Kelly, MD, AGAF, associate professor of medicine at Brown University in Providence, R.I. and co-principal investigator of the AGA FMT National Registry. “Releasing the initial results of the AGA FMT National Registry is an important step toward understanding the true risks and benefits of microbiota therapeutics in a real-world setting.”
This new report details effectiveness and safety outcomes from the first 259 patients enrolled in the registry between December 2017 and September 2019. Almost all participants received FMT using an unknown donor from stool banks. The most common method of FMT delivery was colonoscopy followed by upper endoscopy. Of the 222 participants who returned for the one-month follow-up, 200 participants (90%) had their C. difficile infection cured with 197 of those requiring only a single FMT. Infections were reported in 11 participants, but only 2 were thought to be possibly related to the procedure. FMT response was deemed durable, with recurrence of C. difficile infection in the 6 months after successful FMT occurring in only 4% of participants. This data includes patients with comorbidities, such as inflammatory bowel disease and immunocompromised status, who are typically excluded from FMT clinical trials.
“These initial results show a high success rate of FMT in the real-world setting. We’ll continue to track these patients for 10 years to assess long-term safety, which will be critical to determining the full safety profile of FMT,” added Dr. Kelly.
Ninety percent of patients tracked in the AGA FMT National Registry were cured of Clostridioides difficile infection with few serious side effects.
AGA has released the first results from the NIH-funded AGA Fecal Microbiota Transplantation (FMT) National Registry, the largest real-world study on the safety and effectiveness of FMT. Few serious side effects were reported.
“While the value of fecal microbiota transplantation for treating recurrent C. difficile infection is clear from research studies, the potential long-term consequences of altering a patient’s gut microbiota are not fully known,” says Colleen R. Kelly, MD, AGAF, associate professor of medicine at Brown University in Providence, R.I. and co-principal investigator of the AGA FMT National Registry. “Releasing the initial results of the AGA FMT National Registry is an important step toward understanding the true risks and benefits of microbiota therapeutics in a real-world setting.”
This new report details effectiveness and safety outcomes from the first 259 patients enrolled in the registry between December 2017 and September 2019. Almost all participants received FMT using an unknown donor from stool banks. The most common method of FMT delivery was colonoscopy followed by upper endoscopy. Of the 222 participants who returned for the one-month follow-up, 200 participants (90%) had their C. difficile infection cured with 197 of those requiring only a single FMT. Infections were reported in 11 participants, but only 2 were thought to be possibly related to the procedure. FMT response was deemed durable, with recurrence of C. difficile infection in the 6 months after successful FMT occurring in only 4% of participants. This data includes patients with comorbidities, such as inflammatory bowel disease and immunocompromised status, who are typically excluded from FMT clinical trials.
“These initial results show a high success rate of FMT in the real-world setting. We’ll continue to track these patients for 10 years to assess long-term safety, which will be critical to determining the full safety profile of FMT,” added Dr. Kelly.
Ninety percent of patients tracked in the AGA FMT National Registry were cured of Clostridioides difficile infection with few serious side effects.
AGA has released the first results from the NIH-funded AGA Fecal Microbiota Transplantation (FMT) National Registry, the largest real-world study on the safety and effectiveness of FMT. Few serious side effects were reported.
“While the value of fecal microbiota transplantation for treating recurrent C. difficile infection is clear from research studies, the potential long-term consequences of altering a patient’s gut microbiota are not fully known,” says Colleen R. Kelly, MD, AGAF, associate professor of medicine at Brown University in Providence, R.I. and co-principal investigator of the AGA FMT National Registry. “Releasing the initial results of the AGA FMT National Registry is an important step toward understanding the true risks and benefits of microbiota therapeutics in a real-world setting.”
This new report details effectiveness and safety outcomes from the first 259 patients enrolled in the registry between December 2017 and September 2019. Almost all participants received FMT using an unknown donor from stool banks. The most common method of FMT delivery was colonoscopy followed by upper endoscopy. Of the 222 participants who returned for the one-month follow-up, 200 participants (90%) had their C. difficile infection cured with 197 of those requiring only a single FMT. Infections were reported in 11 participants, but only 2 were thought to be possibly related to the procedure. FMT response was deemed durable, with recurrence of C. difficile infection in the 6 months after successful FMT occurring in only 4% of participants. This data includes patients with comorbidities, such as inflammatory bowel disease and immunocompromised status, who are typically excluded from FMT clinical trials.
“These initial results show a high success rate of FMT in the real-world setting. We’ll continue to track these patients for 10 years to assess long-term safety, which will be critical to determining the full safety profile of FMT,” added Dr. Kelly.
Engage rather than react: A call for hepatologists
In a new practice management commentary, Dr. Meena B. Bansal challenges hepatologists to champion value-based care.
In the September issue of Clinical Gastroenterology and Hepatology, Meena B. Bansal, MD, FAASLD, from Icahn School of Medicine at Mount Sinai, New York, provides clinicians with practical guidance on their essential role in value-based health care. Read the article, which appears in CGH’s Practice Management: The Road Ahead column: How Hepatologists Can Contribute to Value-Based Care.
Since hepatologists care for some of the sickest patients in the system, their role in documenting and managing chronic conditions is paramount to a system’s success in value-based care. Hepatologists can expand their reach by:
- Advocating for improvement of coding specificity.
- Participating in quality improvement work.
- Supporting efforts to create a shift in the cost curve for their high-risk patients.
By highlighting how they can shift the cost curve while improving outcomes, they can advocate for the additional resources needed to care for this high-risk population and can have the opportunity to show the return on investment. With this outlook, hepatologists who “engage” rather than “react” can make a real impact on system leadership and play a key role in this dynamic health care landscape.
Read the full article in the September issue of Clinical Gastroenterology and Hepatology.
In a new practice management commentary, Dr. Meena B. Bansal challenges hepatologists to champion value-based care.
In the September issue of Clinical Gastroenterology and Hepatology, Meena B. Bansal, MD, FAASLD, from Icahn School of Medicine at Mount Sinai, New York, provides clinicians with practical guidance on their essential role in value-based health care. Read the article, which appears in CGH’s Practice Management: The Road Ahead column: How Hepatologists Can Contribute to Value-Based Care.
Since hepatologists care for some of the sickest patients in the system, their role in documenting and managing chronic conditions is paramount to a system’s success in value-based care. Hepatologists can expand their reach by:
- Advocating for improvement of coding specificity.
- Participating in quality improvement work.
- Supporting efforts to create a shift in the cost curve for their high-risk patients.
By highlighting how they can shift the cost curve while improving outcomes, they can advocate for the additional resources needed to care for this high-risk population and can have the opportunity to show the return on investment. With this outlook, hepatologists who “engage” rather than “react” can make a real impact on system leadership and play a key role in this dynamic health care landscape.
Read the full article in the September issue of Clinical Gastroenterology and Hepatology.
In a new practice management commentary, Dr. Meena B. Bansal challenges hepatologists to champion value-based care.
In the September issue of Clinical Gastroenterology and Hepatology, Meena B. Bansal, MD, FAASLD, from Icahn School of Medicine at Mount Sinai, New York, provides clinicians with practical guidance on their essential role in value-based health care. Read the article, which appears in CGH’s Practice Management: The Road Ahead column: How Hepatologists Can Contribute to Value-Based Care.
Since hepatologists care for some of the sickest patients in the system, their role in documenting and managing chronic conditions is paramount to a system’s success in value-based care. Hepatologists can expand their reach by:
- Advocating for improvement of coding specificity.
- Participating in quality improvement work.
- Supporting efforts to create a shift in the cost curve for their high-risk patients.
By highlighting how they can shift the cost curve while improving outcomes, they can advocate for the additional resources needed to care for this high-risk population and can have the opportunity to show the return on investment. With this outlook, hepatologists who “engage” rather than “react” can make a real impact on system leadership and play a key role in this dynamic health care landscape.
Read the full article in the September issue of Clinical Gastroenterology and Hepatology.
Top AGA Community patient cases
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
- Initial results from the FMT National Registry (https://community.gastro.org/posts/22693)
- Practice update: Reducing rates of post endoscopy esophageal adenocarcinoma (https://community.gastro.org/posts/22805)
- Patient case: Eosinophilic gastrointestinal disease (https://community.gastro.org/posts/22743)
- Patient case: Repeat colonoscopy following splenic injury (https://community.gastro.org/posts/22739)
- Windows on Clinical GI Roundtables: Crohn’s disease and gastroparesis
View upcoming Roundtables in the community at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
- Initial results from the FMT National Registry (https://community.gastro.org/posts/22693)
- Practice update: Reducing rates of post endoscopy esophageal adenocarcinoma (https://community.gastro.org/posts/22805)
- Patient case: Eosinophilic gastrointestinal disease (https://community.gastro.org/posts/22743)
- Patient case: Repeat colonoscopy following splenic injury (https://community.gastro.org/posts/22739)
- Windows on Clinical GI Roundtables: Crohn’s disease and gastroparesis
View upcoming Roundtables in the community at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
- Initial results from the FMT National Registry (https://community.gastro.org/posts/22693)
- Practice update: Reducing rates of post endoscopy esophageal adenocarcinoma (https://community.gastro.org/posts/22805)
- Patient case: Eosinophilic gastrointestinal disease (https://community.gastro.org/posts/22743)
- Patient case: Repeat colonoscopy following splenic injury (https://community.gastro.org/posts/22739)
- Windows on Clinical GI Roundtables: Crohn’s disease and gastroparesis
View upcoming Roundtables in the community at https://community.gastro.org/discussions.
AGA announces October GI Forging Forward virtual symposias
Join us for our new GI Forging Forward virtual symposia series, a practical educational training program covering timely topics for GIs through the lens of COVID-19. Experts in the field will present the latest COVID-19 findings, share proven strategies to communicate and manage disaster and crisis situations, and educate participants on evidence-based recommendations to meet today’s evolving needs. Upcoming topics will cover keeping you, your staff and patients safe, new approaches and training in research, leading in times of crisis, and rapid-response guideline development.
Registration for this month’s virtual webinars are now open:
- Meet NIH Leadership: Minorities health disparities, research and career development: Oct. 15, 2020, 5:30 p.m. EDT
- Effective leadership in times of crisis: Oct. 22, 2020, 5:30 p.m. EDT
For more information, visit www.gastro.org/GIForgingForward.
Join us for our new GI Forging Forward virtual symposia series, a practical educational training program covering timely topics for GIs through the lens of COVID-19. Experts in the field will present the latest COVID-19 findings, share proven strategies to communicate and manage disaster and crisis situations, and educate participants on evidence-based recommendations to meet today’s evolving needs. Upcoming topics will cover keeping you, your staff and patients safe, new approaches and training in research, leading in times of crisis, and rapid-response guideline development.
Registration for this month’s virtual webinars are now open:
- Meet NIH Leadership: Minorities health disparities, research and career development: Oct. 15, 2020, 5:30 p.m. EDT
- Effective leadership in times of crisis: Oct. 22, 2020, 5:30 p.m. EDT
For more information, visit www.gastro.org/GIForgingForward.
Join us for our new GI Forging Forward virtual symposia series, a practical educational training program covering timely topics for GIs through the lens of COVID-19. Experts in the field will present the latest COVID-19 findings, share proven strategies to communicate and manage disaster and crisis situations, and educate participants on evidence-based recommendations to meet today’s evolving needs. Upcoming topics will cover keeping you, your staff and patients safe, new approaches and training in research, leading in times of crisis, and rapid-response guideline development.
Registration for this month’s virtual webinars are now open:
- Meet NIH Leadership: Minorities health disparities, research and career development: Oct. 15, 2020, 5:30 p.m. EDT
- Effective leadership in times of crisis: Oct. 22, 2020, 5:30 p.m. EDT
For more information, visit www.gastro.org/GIForgingForward.